✦ LIBER ✦

Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma

✍ Scribed by T. Olencki; D. Peereboom; L. Wood; G. T. Budd; A. Novick; J. Finke; D. McLain; P. Elson; R. M. Bukowski

Publisher: Springer-Verlag
Year: 2001
Tongue: English
Weight: 103 KB
Volume: 127
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320000211

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of intravenous gemcitab

A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH

Phase II trial of 5-fluorouracil, interf

Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

A phase I trial of 5-fluorouracil, folin

A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma

✍ Ronald M. Bukowski; Go Inoshita; Prasad Yalavarthi; Siva Murthy; Vicki Gibson; G 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 2 views

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

A Phase II trial of 5-fluorouracil and r

A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma

✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 3 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do